August 15, 2019 / 7:52 PM / 5 days ago

BRIEF-Roche's Personalized Cancer Treatment Wins FDA Approval

Aug 15 (Reuters) - U.S. Food and Drug Administration:

* FDA APPROVES THIRD ONCOLOGY DRUG THAT TARGETS A KEY GENETIC DRIVER OF CANCER, RATHER THAN A SPECIFIC TYPE OF TUMOR

* U.S. FDA - GRANTED ACCELERATED APPROVAL TO ROZLYTREK, A TREATMENT FOR PATIENTS WHOSE CANCERS HAVE SPECIFIC GENETIC DEFECT, NTRK GENE FUSION

* U.S. FDA - ROZLYTREK ALSO APPROVED FOR TREATMENT OF ADULTS WITH NON-SMALL CELL LUNG CANCER WHOSE TUMORS ARE ROS1-POSITIVE AND IS METASTATIC

* U.S. FDA - APPROVAL OF ROZLYTREK WAS GRANTED TO GENENTECH INC Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below